Picture EBD Group World of Partnering Opportunities 650x100px

Document › Details

CRISPR Therapeutics AG. (2/21/23). "Press Release: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results". Zug & Boston, MA.

	Organisation	CRISPR Therapeutics AG (Nasdaq: CRSP)
	Group	CRISPR Therapeutics (Group)
	Organisation 2	Vertex Pharmaceuticals Inc. (Nasdaq: VRTX)
	Group	Vertex Pharmaceuticals (Group)
	Product	exagamglogene autotemcel (exa-cel) (formerly CTX001)
	Product 2	CTX130 allogeneic CAR T-cell therapy
	Person	Harding, Alex (CRISPR Therapeutics 202301– Head BusDev before Remix Theraepeutics + Atlas Venture)
	Person 2	Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)

Original document
accessed by [iito] on 2023-02-27

Record changed: 2024-01-20

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for CRISPR Therapeutics (Group)

[1] CRISPR Therapeutics AG. (2/13/24). "Press Release: CRISPR Therapeutics Announces $280 Million Registered Direct Offering". Zug & Boston, MA....
[2] CRISPR Therapeutics AG. (2/13/24). "Press Release: European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, Casgevy (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)". Z...
[3] CRISPR Therapeutics AG. (1/3/24). "Press Release: CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference". Zug & Boston, MA....
[4] CRISPR Therapeutics AG. (6/13/23). "Pressemitteilung: CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference". Zug & Cambridge, MA....
[5] CRISPR Therapeutics AG. (4/13/23). "Press Release: CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference". Zug & Cambridge, MA....
[6] CRISPR Therapeutics AG. (4/3/23). "Press Release: CRISPR Therapeutics and Vertex Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for Exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalas...
[7] CRISPR Therapeutics AG. (3/29/23). "Press Release: CRISPR Therapeutics Announces Departure of Board Member". Zug & Boston, MA....
[8] CRISPR Therapeutics AG. (3/27/23). "Press Release: CRISPR Therapeutics and Vertex Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes". Boston, MA & Zug....
[9] CRISPR Therapeutics AG. (3/13/23). "Press Release: CRISPR Therapeutics Announces Transition of Chief Financial Officer". Zug & Boston, MA....
[10] CRISPR Therapeutics AG. (2/27/23). "Press Release: CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference". Zug & Boston, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]